Epilepsy Pharmacogenomics: delivering

biomarkers for clinical use

Short Facts

EpiPGX is a unique pharmacogenomics project which brings together renowned scientists from various academic institutions and SMEs throughout Europe. The project aims to identify genome-based biomarkers for use in clinical practice to individualise treatment of epilepsy, and stratify patients for clinical trials, aiming to avoid chronicity, prevent relapse and reduce adverse drug reactions (ADRs). The project uses genome-wide analyses, including next-generation sequencing, in large, well-phenotyped patient cohorts to identify genome-based biomarkers, to improve use of current antiepileptic drugs (AEDs) and identify new therapy targets.

The EpiPGX project received funding by the EC from 2011 – 2015 and is continuing its effort. The project lead is Sanjay Sisodiya (University College London).

The EpiPGX consortium consists of 15 participating institutions based in different EU member states.

Prof. Sanjay Sisodiya

Professor of Neurology, UCL Institute of Neurology, and Honorary Consultant Neurologist at the National Hospital for Neurology and Neurosurgery, UK